These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1075 related articles for article (PubMed ID: 8203723)
1. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723 [TBL] [Abstract][Full Text] [Related]
2. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier. Lebens M; Holmgren J Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476 [TBL] [Abstract][Full Text] [Related]
3. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556 [TBL] [Abstract][Full Text] [Related]
4. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects]. Carrada Bravo T Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024 [TBL] [Abstract][Full Text] [Related]
5. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897 [TBL] [Abstract][Full Text] [Related]
6. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Lycke N Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758 [TBL] [Abstract][Full Text] [Related]
8. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Lycke N; Holmgren J Immunology; 1986 Oct; 59(2):301-8. PubMed ID: 3021614 [TBL] [Abstract][Full Text] [Related]
9. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. Liang XP; Lamm ME; Nedrud JG J Immunol; 1988 Sep; 141(5):1495-501. PubMed ID: 2842395 [TBL] [Abstract][Full Text] [Related]
10. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice. Van der Heijden PJ; Bianchi AT; Dol M; Pals JW; Stok W; Bokhout BA Immunology; 1991 Jan; 72(1):89-93. PubMed ID: 1705237 [TBL] [Abstract][Full Text] [Related]
11. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Holmgren J; Lycke N; Czerkinsky C Vaccine; 1993 Sep; 11(12):1179-84. PubMed ID: 8256498 [TBL] [Abstract][Full Text] [Related]
12. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. Hajishengallis G; Hollingshead SK; Koga T; Russell MW J Immunol; 1995 May; 154(9):4322-32. PubMed ID: 7722290 [TBL] [Abstract][Full Text] [Related]
13. A review of the current status of enteric vaccines. Levine MM; Noriega F P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876 [TBL] [Abstract][Full Text] [Related]
14. Induction of an enteric Ig-response against ovalbumin and stimulation of the response by cholera toxin and its B-subunit in mice. Bianchi AT; Zwart RJ; Van der Heijden PJ Reg Immunol; 1990-1991; 3(3):131-8. PubMed ID: 2098068 [TBL] [Abstract][Full Text] [Related]
15. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283 [TBL] [Abstract][Full Text] [Related]
16. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Nyström-Asklin J; Adamsson J; Harandi AM Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617 [TBL] [Abstract][Full Text] [Related]
17. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. Nochi T; Yuki Y; Katakai Y; Shibata H; Tokuhara D; Mejima M; Kurokawa S; Takahashi Y; Nakanishi U; Ono F; Mimuro H; Sasakawa C; Takaiwa F; Terao K; Kiyono H J Immunol; 2009 Nov; 183(10):6538-44. PubMed ID: 19880451 [TBL] [Abstract][Full Text] [Related]
18. Selective induction of mucosal immune responses to 2-acetylaminofluorene. Silbart LK; McAleer F; Rasmussen MV; Goslinoski L; Keren DF; Finley A; Van Kruiningen HJ; Winchell JM Anticancer Res; 1996; 16(2):651-60. PubMed ID: 8687111 [TBL] [Abstract][Full Text] [Related]
19. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
20. Cholera toxin and related enterotoxins: a cell biological and immunological perspective. de Haan L; Hirst TR J Nat Toxins; 2000 Aug; 9(3):281-97. PubMed ID: 10994530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]